Roy A. Jensen, MD, combines exceptional experience in the laboratory and international leadership in pathology to lead The University of Kansas Cancer Center. Since becoming director in 2004, he has recruited a world-class leadership team and implemented a vision toward achieving the National Cancer Institute’s (NCI) designation as a Comprehensive Cancer Center. Dr. Jensen has been at the forefront in the characterization of premalignant and malignant breast lesions, particularly the earliest genetic alterations that result in breast neoplasia, and the transition from situ disease to invasion. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of BRCA1 function contributes to the development of breast cancer.
Dr. Jensen was born in Gardner, Kansas and earned his bachelor’s degree in Biology from Pittsburg State University. He went on to receive his Medical Degree from Vanderbilt University in 1984. Following his fellowship training at the National Cancer Institute, Dr. Jensen joined the faculty of Vanderbilt in 1991 in the Departments of Pathology and Cell Biology.
Medical research finds ways to help people live longer, improve their quality of life and manage or cure disease. This is possible because of the people who volunteer to participate in clinical trials.